Individualizing therapy for the hematologic malignancies: the stuff of genes and dreams


Published: June 23, 2009
Abstract Views: 158
PDF: 256
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Treatment for hematologic malignancies has traditionally included non-specific cytotoxic agents, such as anthracyclines vinca alkyloids, alkylating agents, and corticosteroids, most often in empiric combinations. In recent years, major advances in treatment have resulted from the availability of novel agents that either target surface antigens or cellular pathways.

Supporting Agencies


Cheson, B. (2009). Individualizing therapy for the hematologic malignancies: the stuff of genes and dreams. Hematology Meeting Reports (formerly Haematologica Reports), 2(5). https://doi.org/10.4081/hmr.v2i5.741

Downloads

Citations